James R. Cerhan spends much of his time researching Internal medicine, Risk factor, Lymphoma, Prospective cohort study and Odds ratio. His Internal medicine research is multidisciplinary, incorporating elements of Endocrinology and Oncology. His Risk factor research is multidisciplinary, incorporating perspectives in Body mass index, Environmental health, Cancer registry, Gynecology and Cohort.
His Lymphoma course of study focuses on Chronic lymphocytic leukemia and Single-nucleotide polymorphism, Locus, B cell and Genome-wide association study. His work carried out in the field of Prospective cohort study brings together such families of science as Vitamin D and neurology, Absolute risk reduction, Confounding and Hazard ratio. His Odds ratio research incorporates themes from Epidemiology, Case-control study, Allele, Allele frequency and Confidence interval.
James R. Cerhan mainly investigates Internal medicine, Oncology, Lymphoma, Immunology and Cancer. Prospective cohort study, Odds ratio, Risk factor, Follicular lymphoma and Diffuse large B-cell lymphoma are among the areas of Internal medicine where James R. Cerhan concentrates his study. His studies in Prospective cohort study integrate themes in fields like Relative risk and Cohort.
The concepts of his Risk factor study are interwoven with issues in Body mass index, Incidence, Epidemiology, Cohort study and Gynecology. His Oncology study also includes fields such as
James R. Cerhan focuses on Internal medicine, Lymphoma, Oncology, Diffuse large B-cell lymphoma and Follicular lymphoma. His research brings together the fields of Gastroenterology and Internal medicine. His Lymphoma research incorporates elements of Cancer, Survival rate, Quality of life, Biopsy and Disease.
The various areas that James R. Cerhan examines in his Oncology study include Odds ratio, International Prognostic Index and Cohort. He combines subjects such as Cancer research and Clinical trial with his study of Diffuse large B-cell lymphoma. His Hazard ratio study integrates concerns from other disciplines, such as Proportional hazards model and Cohort study.
James R. Cerhan mainly focuses on Internal medicine, Lymphoma, Oncology, Follicular lymphoma and Diffuse large B-cell lymphoma. All of his Internal medicine and Cohort study, Prospective cohort study, Odds ratio, Proportional hazards model and Cancer investigations are sub-components of the entire Internal medicine study. In his study, B symptoms, Epidemiology, Response rate and Family medicine is inextricably linked to Cohort, which falls within the broad field of Prospective cohort study.
His research in Lymphoma intersects with topics in Survival rate, Cancer research and Hazard ratio. His Oncology study combines topics in areas such as Young adult, Hematology, Disease and Chronic lymphocytic leukemia. His Primary Mediastinal Large B-Cell Lymphoma study, which is part of a larger body of work in Diffuse large B-cell lymphoma, is frequently linked to Asterisk, bridging the gap between disciplines.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Body-Mass Index and Mortality among 1.46 Million White Adults
Amy Berrington De Gonzalez;Patricia Hartge;James R. Cerhan;Alan J. Flint.
The New England Journal of Medicine (2010)
Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents
Emanuele Di Angelantonio;Shilpa N Bhupathiraju;David Wormser;Pei Gao;Pei Gao.
The Lancet (2016)
Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study
Linda A. Merlino;Jeffrey Curtis;Ted R. Mikuls;James R. Cerhan.
Arthritis & Rheumatism (2004)
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing
Jens G. Lohr;Petar Stojanov;Petar Stojanov;Michael S. Lawrence;Daniel Auclair.
Proceedings of the National Academy of Sciences of the United States of America (2012)
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
Bjoern Chapuy;Chip Stewart;Andrew J Dunford;Jaegil Kim.
Nature Medicine (2018)
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Michael Crump;Sattva S. Neelapu;Umar Farooq;Eric Van Den Neste.
Body Fat Distribution and 5-Year Risk of Death in Older Women
Aaron R. Folsom;Susan A. Kaye;Thomas A. Sellers;Ching Ping Hong.
2016 US lymphoid malignancy statistics by World Health Organization subtypes.
Lauren R. Teras;Carol E. DeSantis;James R. Cerhan;Lindsay M. Morton.
CA: A Cancer Journal for Clinicians (2016)
Type I and II Endometrial Cancers: Have They Different Risk Factors?
Veronica Wendy Setiawan;Hannah P. Yang;Malcolm C. Pike;Malcolm C. Pike;Susan E. McCann;Susan E. McCann.
Journal of Clinical Oncology (2013)
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
Carla Casulo;Michelle Byrtek;Keith L. Dawson;Xiaolei Zhou.
Journal of Clinical Oncology (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: